Edgewise Therapeutics, Inc.
EWTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $127 | $91 | $54 | $32 |
| G&A Expenses | $32 | $23 | $18 | $11 |
| SG&A Expenses | $32 | $23 | $18 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $159 | $114 | $72 | $43 |
| Operating Income | -$159 | -$114 | -$72 | -$43 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $25 | $14 | $4 | $0 |
| Pre-Tax Income | -$134 | -$100 | -$68 | -$43 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$134 | -$100 | -$68 | -$43 |
| % Margin | – | – | – | – |
| EPS | -1.45 | -1.57 | -1.26 | -0.86 |
| % Growth | 7.6% | -24.6% | -46.5% | – |
| EPS Diluted | -1.45 | -1.57 | -1.26 | -0.86 |
| Weighted Avg Shares Out | 92 | 64 | 54 | 50 |
| Weighted Avg Shares Out Dil | 92 | 64 | 54 | 50 |
| Supplemental Information | – | – | – | – |
| Interest Income | $25 | $14 | $3 | $0 |
| Interest Expense | $0 | $0 | $4 | $0 |
| Depreciation & Amortization | $2 | $2 | $1 | $0 |
| EBITDA | -$157 | -$113 | -$71 | -$43 |
| % Margin | – | – | – | – |